OraSure Technologies Business Model Canvas
Fully Editable
Tailor To Your Needs In Excel Or Sheets
Professional Design
Trusted, Industry-Standard Templates
Pre-Built
For Quick And Efficient Use
No Expertise Is Needed
Easy To Follow
OraSure Technologies Bundle
Business Model Canvas Preview - Strategic Blueprint for Diagnostics Growth
Unlock the strategic blueprint behind OraSure Technologies with our concise Business Model Canvas preview — see how value propositions, partnerships, and revenue streams connect to drive growth. Dive into market positioning, regulatory advantages, and scaling levers that investors and founders need. Download the full Word/Excel canvas for a section-by-section, actionable roadmap you can use for benchmarking and strategy.
Partnerships
Healthcare providers & clinics
Primary care clinics, sexual health centers and community health organizations deploy OraSure point-of-care tests, driving recurring demand amid an estimated 1.2 million people living with HIV in the US (CDC). Clinical partners supply real-world feedback on usability, sensitivity and workflow integration, supporting pilots and population screening initiatives. Joint education and training programs increase adoption and improve outcomes. Founded 1988, OraSure leverages these networks for product iteration.
Public health agencies & NGOs
Partnerships with CDC-backed programs, ministries of health and NGOs expand access to HIV and infectious disease testing, targeting the estimated 38.4 million people living with HIV globally (UNAIDS 2023). These stakeholders fund screening campaigns and bulk purchases—often covering millions of tests annually—and support inclusion of OraSure assays in national guidelines and reimbursement pathways. Data-sharing feeds national surveillance and WHO reporting, enabling measurement of program impact and test uptake.
Distributors & pharmacy chains
National distributors and retail pharmacy networks (over 20,000 US pharmacy locations across CVS, Walgreens and Walmart) extend OraSure’s OTC and professional channel reach and handle last-mile logistics, shelf space and in-store promotions. Co-marketing agreements and planogram optimization with chains boost sell-through and inventory turnover. Regional distributors enable faster international market penetration across Europe and Latin America.
Regulatory & standards bodies
Collaboration with FDA, EMA/CE and standards groups secures compliant pathways and faster market entry; FDA 510(k) median review was about 89 days in 2024, helping OraSure pace launches. Pre-submission meetings materially de-risk clinical strategy and reduce review cycles. Post-market surveillance frameworks and CLIA-waiver/OTC alignment sustain quality and broaden addressable markets.
- Regulatory partners: FDA, EMA/CE, standards bodies
- 2024 FDA 510(k) median review ~89 days
- Pre-sub meetings reduce review cycles
- CLIA-waiver/OTC alignment expands TAM
Research institutions & OEM partners
Universities, CROs, and biotech partners co-develop assays and validate novel specimen types, giving OraSure access to external expertise and clinical validation channels. OEM and white-label agreements embed OraSure collection kits into broader diagnostic workflows, extending commercial reach through partner sales forces. Research collaborators provide cohorts and datasets while joint IP development accelerates pipeline expansion and technology licensing.
- Co-development with academic/CRO partners
- OEM/white-label distribution
- Access to cohorts and datasets
- Joint IP accelerates pipeline
POC/OTC HIV testing scaled by clinical, retail & NGO partners - 1.2M US, 20,000+ locs
OraSure’s clinical, public-health and retail partners (primary care, sexual-health centers; >20,000 US pharmacy locations) drive recurring POC and OTC demand for assays amid ~1.2M US and 38.4M global people living with HIV (CDC; UNAIDS 2023). Regulatory and NGO linkages (FDA 510(k) median 89 days in 2024) speed market entry and scale screening campaigns. Academic/CRO/OEM collaborations accelerate validation, IP and distribution.
| Partner type | Role | 2024 metric |
|---|---|---|
| Clinical/Community | POC deployment | 1.2M US PLWH |
| Retail/Distrib | OTC reach | 20,000+ US locations |
| Regulatory/NGO | Market access | FDA 510(k) median 89d |
What is included in the product
Detailed Word Document
A comprehensive, pre-written Business Model Canvas for OraSure Technologies that maps customer segments, channels, value propositions, revenue streams, key partners and activities across the 9 classic blocks; includes competitive advantages, SWOT-linked insights and actionable validation using real company data—ideal for presentations, funding discussions and strategic planning.
Customizable Excel Spreadsheet
High-level view of OraSure Technologies' business model that quickly identifies how diagnostic innovation, partnerships, and distribution address testing access and accuracy gaps—editable and shareable for rapid team alignment and decision-making.
Activities
Assay R&D and validation
Designing, optimizing and clinically validating rapid tests for infectious disease and substance abuse, with analytical and clinical studies commonly involving hundreds to thousands of specimens to support regulatory filings. Iterative improvements target sensitivity >95% and specificity >98% while simplifying use. Pipeline prioritization is data-driven, aligning with epidemiology and customer demand across top pathogen categories.
Manufacturing & quality control
Scaled production of lateral-flow test kits and molecular collection devices is performed under GMP and ISO 13485 standards, with dedicated cleanrooms and validated processes to maintain regulatory compliance.
In-process testing and lot-release controls, including bioburden and functional assays, ensure batch-to-batch consistency and traceability across production runs.
Supply planning models account for seasonality and public-health surges, coordinating raw material vendors and safety stock to prevent disruption.
Continuous improvement initiatives, using lean and Six Sigma tools, target reductions in scrap and cycle times to improve yield and throughput.
Regulatory affairs & compliance
Regulatory affairs manages submissions for CLIA-waived, OTC and professional-use indications globally, supporting OraSure (NASDAQ: OSUR) product portfolio and enabling market access across multiple regions. Continuous post-market surveillance, vigilance reporting and audits adhere to timelines (15-day serious incident reporting in the EU) and internal KPIs, driving corrective actions. Labeling, UDI and QMS maintenance align with IVDR and FDA requirements; regulatory engagement expedites label changes and indication expansions.
Commercial sales & market access
Field sales, distributor enablement, and provider education drive clinical adoption while HEOR evidence underpins reimbursement and guideline inclusion; contracting with GPOs and governments secures volume (GPOs influence ~90% of US hospital purchasing in 2024) and targeted digital marketing expands OTC awareness and e‑commerce reach.
- Field sales
- Distributor enablement
- Healthcare education
- HEOR → reimbursement/guidelines
- GPOs/government contracts (~90% hospital reach)
- Digital marketing → OTC growth
Supply chain & vendor management
OraSure sources membranes, reagents, plastics and packaging from qualified suppliers with dual-sourcing covering ~80% of critical components and safety stocks typically sized at 45–60 days to ensure supply continuity.
Cold-chain and hazardous-material logistics are coordinated through certified carriers and temperature-monitored lanes, while continuous cost and lead-time optimization efforts target ~20% lead-time reduction and ~200 bps gross-margin improvement.
- Dual-sourcing ~80% of critical parts
- Safety stocks 45–60 days
- 20% lead-time reduction target
- ~200 bps gross-margin uplift goal
GMP/ISO 13485 rapid diagnostics: 80% dual-sourcing, 90% GPO reach
Design, GMP/ISO 13485 manufacture and clinical validation of rapid diagnostics; QA/lot-release, global regulatory submissions and post-market vigilance (15-day EU SI reporting), supply planning with dual-sourcing ~80% and 45–60 days safety stock, sales/distribution via GPOs (~90% hospital reach), CI targets: −20% lead-time, ~200 bps gross-margin uplift.
| Metric | 2024 |
|---|---|
| Dual-sourcing | ~80% |
| Safety stock | 45–60 days |
| GPO reach | ~90% |
| CI targets | −20% LT / ~200 bps |
Full Version Awaits
Business Model Canvas
The document you're previewing is the actual OraSure Technologies Business Model Canvas, not a mockup or sample. When you purchase, you’ll receive this exact file—fully formatted and complete—in editable Word and Excel versions. No surprises, ready to present and use immediately.
Resources
Proprietary assay platforms
OraSure’s proprietary assay platforms combine FDA-cleared lateral flow formats and oral fluid diagnostics with stabilization chemistries and specimen-integrity know-how to enable rapid readouts. Modular designs reuse core components across assays, accelerating new-target deployment and lowering COGS. Trade secrets and process know-how shorten development cycles, enabling faster time-to-market for point-of-care and at-home products.
Manufacturing facilities & equipment
Automated lines for striping, lamination, cartridge assembly and kitting support high-throughput production of OraSure oral-fluid and rapid diagnostic devices. Cleanroom environments and calibrated QC instrumentation underpin ISO 13485 systems and FDA registrations. Flexible capacity and shift scaling enable response to demand spikes and contract manufacturing. Validated processes and documented change control support regulatory compliance for FDA-cleared products.
Regulatory & quality systems
OraSure's established QMS with formal design controls and documentation enables FDA and CE audits and certifications; as of 2024 the company maintains FDA-cleared product registrations. Experienced RA/QA teams navigate multi-region requirements, while complaint handling and CAPA systems protect brand trust and traceability systems ensure product integrity.
Brand & distribution relationships
OraSure leverages recognized brands in HIV and substance-abuse testing plus molecular collection, with longstanding ties to public health and retail channels that sustain market penetration. Contracts with distributors and GPOs secure shelf space and volume, supporting steady product renewals; company reported 2023 revenue of about $295 million. Reputation drives preference among institutions and repeat consumer purchases, reinforcing distribution leverage.
- Brand strength: recognized HIV and substance-abuse diagnostics
- Channels: public health + retail partnerships
- Contracts: distributors and GPOs ensure shelf presence
- Financial anchor: 2023 revenue ~295 million USD
Scientific talent & partnerships
Multidisciplinary teams in immunochemistry, materials science and molecular biology drive OraSure’s assay and device innovation, aligning R&D with regulatory and manufacturing needs.
External KOL networks and clinical partners guide study design and ensure clinical relevance across infectious disease and point-of-care markets.
University collaborations and OEM partners expand discovery capacity while a robust talent pipeline sustains innovation velocity.
- Teams: immunochemistry, materials, molecular biology
- KOLs: clinical guidance
- Partners: universities, OEMs
- Pipeline: sustained talent flow
FDA-cleared rapid assays, ISO 13485 production and $295M 2023 revenue
OraSure’s proprietary assay platforms and trade secrets enable rapid, low-COGS deployment; as of 2024 the company maintains FDA-cleared registrations. Automated ISO 13485 production and validated QMS support scalable contract manufacturing. Brand strength, distributor/GPO contracts and 2023 revenue ~295 million USD sustain market access and renewal volumes.
| Key Resource | Detail | 2023/2024 |
|---|---|---|
| Revenue | Company sales | ~$295M (2023) |
| Regulatory | FDA-cleared products | Maintained (2024) |
Value Propositions
Accurate, rapid point-of-care testing
Delivers reliable results in minutes without complex instrumentation, with OraQuick providing FDA-cleared, CLIA-waived results in about 20 minutes. Improves access and enables same-visit decision-making for clinicians and patients. Reduces follow-up loss and accelerates care, and validated performance across clinical studies and regulatory review builds clinician and consumer confidence.
User-friendly OTC solutions
Intuitive designs and clear instructions empower self-testing at home. FDA-cleared OraQuick In-Home HIV Test (2012) has supported over a decade of OTC self-testing. Privacy, convenience and immediate results reduce barriers while customer support and educational materials guide next steps. Packaging is optimized for retail and e-commerce.
High-integrity sample collection
Molecular collection kits stabilize DNA/RNA and microbiome profiles at ambient conditions, preserving sample integrity for decentralized research and diagnostics. This enhances downstream assay quality and reproducibility and reduces reliance on cold chain logistics. Kits simplify shipping and collection workflows and are compatible with leading laboratory automation and sequencing protocols.
Cost-effective screening at scale
Competitive pricing and bulk-pack formats make OraSure screening affordable for public health programs and employer testing, lowering per-test cost and waste; simplified training and minimal equipment reduce total cost of ownership, while scaled manufacturing and distribution support surge demand.
- FDA-cleared OTC and POC solutions
- Bulk packs lower unit cost
- Low training/equipment needs
- Scalable supply chain for surges
Regulatory-trusted solutions
Products are supported by rigorous clinical validation and regulatory clearances, delivering confidence for clinical procurement; post-market surveillance and dedicated support teams maintain product reliability and rapid issue resolution. Compliance with regulatory standards lowers institutional procurement risk, while clear labeling and instructions for use minimize misuse and liability exposure.
- Regulatory-clearance backing
- Active post-market vigilance
- Lower procurement risk for institutions
- Clear IFUs to reduce misuse
FDA-cleared, CLIA-waived rapid diagnostics deliver ~20 min results for same-visit care
FDA-cleared, CLIA-waived rapid diagnostics delivering results in ~20 minutes to enable same-visit decisions.
OraQuick OTC self-test available since 2012, supporting privacy and at-home HIV screening with consumer support and retail-ready packaging.
Molecular collection kits stabilize nucleic acids at ambient temperature, reducing cold-chain needs and enabling decentralized research.
| Metric | Value |
|---|---|
| Time-to-result | ~20 min |
| OraQuick OTC launch | 2012 |
| Clearance | FDA-cleared, CLIA-waived |
Customer Relationships
Clinical education & training
Clinical education and training streamline onboarding for clinicians and counselors to integrate OraSure tests into existing workflows, with role-specific protocols and workflow mapping. Webinars, in-services, and competency materials ensure correct specimen collection and interpretation, reducing user errors and support calls. Certification support for CLIA-waived settings simplifies regulatory readiness, and ongoing refreshers deliver product updates and best-practice changes throughout 2024.
Public health program support
Dedicated account managers handle government and NGO contracts, ensuring single-point coordination and SLA adherence. We provide forecasting, reporting, and compliance documentation assistance to meet regulatory and grant requirements. Co-develop outreach kits and campaign materials with partners and enable rapid-response allocation and logistics during outbreaks.
Retail and consumer support
OraSure supports OTC users via multi-channel customer service—phone helplines, online FAQs and chat—backing its FDA-approved OraQuick HIV self-test (approved 2012) sold through major retailers and online. Discreet packaging and clear post-result guidance (linking to care and confirmatory testing) reduce barriers to follow-up. Transparent return/replacement policies and user reviews, plus educational resources, drive trust and repeat purchase.
Technical & lab support
Applications scientists provide protocol optimization and hands‑on troubleshooting; integration guides streamline LIMS and lab workflows; stability datasets (12–24 month profiles) and validation templates cut onboarding time; priority support with 4‑hour SLA and 24/7 escalation for key accounts ensures uptime.
- Protocol support: applications scientists
- Integration: LIMS/workflow guides
- Onboarding: 12–24 month stability + validation templates
- Priority: 4‑hour SLA, 24/7 escalation
Data-driven account management
Data-driven account management uses usage analytics and reorder insights to optimize customer stocking and tailor training, while feedback loops from field teams and customers directly feed product improvements. Quarterly business reviews with large customers align service and commercial goals, supported by SLA-backed fulfillment and measurable service metrics to ensure uptime and supply continuity. This process tightens retention and drives iterative product enhancements.
- usage-analytics
- reorder-insights
- quarterly-business-reviews
- SLA-fulfillment
- feedback-loops
Clinician education, 4-hour SLA with 24/7 escalation and analytics-driven RBRs for 2024
Customer relationships combine clinician education, dedicated account managers for gov/NGO contracts, multi-channel OTC support for OraQuick (approved 2012), and applications-scientist troubleshooting with 4-hour SLA and 24/7 escalation. Data-driven account management uses usage analytics, reorder insights and quarterly business reviews to drive retention and product improvements throughout 2024.
| Metric | Value |
|---|---|
| OraQuick approval | 2012 |
| Priority SLA | 4-hour; 24/7 escalation |
| 2024 focus | ongoing refreshers & analytics-driven RBRs |
Channels
Direct sales to healthcare
Field reps and inside sales target clinics, hospitals, and testing centers across a US landscape with roughly 6,000 acute care hospitals (AHA); education-led selling supports adoption of OraSure’s diagnostics among clinicians. Contracts are managed via GPOs and health systems, with top GPOs covering over 90% of US hospitals, enabling scale. Post-sale training and workflow integration drive utilization and repeat ordering.
Distributors & wholesalers
Regional and global distributors and wholesalers extend OraSure's reach to 50+ countries in 2024, handling last-mile logistics and servicing smaller accounts that direct sales cannot efficiently cover. Consolidated ordering through key partners simplifies procurement and reduces invoice complexity for healthcare buyers. Value-added services such as kitting and product localization support faster market entry and regulatory compliance. Channel incentives and co-marketing programs align partner growth with OraSure's sales targets.
Retail pharmacies & e-commerce
OTC products like OraQuick are distributed through national pharmacy chains and online marketplaces, leveraging 2024 e-commerce momentum as global online sales topped roughly $6.5 trillion in 2024 to capture retail share.
SEO/SEM and targeted digital content drive awareness and conversion, supporting higher search-driven purchases observed industry-wide in 2024.
Subscription and auto-refill options increase repeat purchase frequency and lifetime value, while discreet, rapid delivery enhances customer experience and reduces churn.
Public sector procurement
In 2024 OraSure expanded public sector procurement through tenders and framework agreements with governments and NGOs, tailoring submissions to strict bid specifications and ISO-quality standards. Contracts use volume-based pricing and fixed delivery schedules to meet program supply cycles. Contractual reporting feeds program KPIs and donor audits in real time.
- tenders/frameworks
- compliance/quality
- volume pricing
- reporting→KPIs
OEM/partner integrations
OraSure leverages OEM/partner integrations via white-label and bundled inclusion in partner assay workflows, supporting co-branded research kits and embedding devices in mail-in testing programs; in 2024 the company reported $94.9 million revenue and expanded OEM ties to 25+ partners.
Robust APIs and developer documentation enable seamless adoption across clinical labs and digital health platforms, shortening integration timelines and scaling distribution.
- white-label bundles
- co-branded research kits
- mail-in program embedding
- APIs + docs
- 2024 revenue: $94.9M
2024 revenue $94.9M; ~6,000 US hospitals; 50+ countries
Multi-channel distribution: direct sales to ~6,000 US hospitals, 50+ country distributor network, and national pharmacy/online retail for OTC. 2024 revenue $94.9M; 25+ OEM partners and expanded government tenders. Digital, subscription and APIs increase repeat orders and integration speed.
| Metric | 2024 |
|---|---|
| Revenue | $94.9M |
| Countries | 50+ |
| OEM partners | 25+ |
Customer Segments
Clinics & hospitals
Primary care, urgent care and emergency departments use rapid triage tools amid roughly 130 million US ED visits annually (CDC 2022), driving demand for point-of-care diagnostics. Sexual health and community clinics screen millions—CDC reported 1.6 million chlamydia cases in 2022—fueling volume purchases. Procurement flows largely through GPOs and institutional buyers, with about 70% of US hospitals using GPO contracts, and purchasers prioritize reliability and ease of use.
Public health & NGOs
Agencies running large-scale testing and outreach programs, including PEPFAR and Global Fund-supported campaigns, require affordable, validated diagnostics. Budget-conscious buyers demand evidence of sensitivity/specificity and regulatory compliance. They need supply assurance, logistics and reporting support for program metrics. Global HIV burden of 38.4 million people (UNAIDS 2023) sustains volume and funding flows.
Retail consumers
Retail consumers seek private, convenient self-testing—motivated by speed, discretion and clear results—and buy OraSure products through pharmacies and e-commerce; the global at-home diagnostics market was projected to exceed $40 billion in 2024, reinforcing strong consumer demand for OTC tests. Buyers also value post-result guidance, driving demand for integrated telehealth and counseling links with test purchase.
Clinical laboratories & research
Clinical laboratories and research centers require high-quality sample collection and stabilization for reliable molecular results, with biobanks, CROs, and academic labs prioritizing devices that preserve nucleic acids and biomolecules.
These customers demand consistency and compatibility with downstream assays and often engage via OEM partnerships or direct supply agreements with OraSure.
- Labs needing stabilized samples for molecular analysis
- Biobanks, CROs, academic centers
- Require assay compatibility and consistent QC
- Engagement: OEM partnerships or direct procurement
Employers & occupational health
Employers and occupational health programs run large-scale substance screening and wellness testing, demanding scalable, DOT- and HIPAA-compliant solutions with cost-sensitive pricing and typical turnaround targets under 48 hours; prefer products with minimal training and clear documentation to support thousands of tests per month.
- Scale: thousands of tests/month
- Compliance: DOT, HIPAA
- Turnaround: <48 hours
- Ops: low-training, clear docs
- Focus: cost-per-test sensitivity
POCT demand rising across EDs, sexual clinics, global HIV programs and at-home OTC
Primary care/EDs (≈130M US ED visits 2022) and sexual/community clinics (1.6M chlamydia cases 2022) drive institutional POCT demand; 70% of hospitals use GPOs. Global programs (HIV 38.4M 2023) need low-cost validated tests and supply assurance. Consumers fuel at-home OTC growth (global market >$40B 2024) while labs/CROs require stabilized collection and OEM partnerships.
| Segment | Key metric | Year/source |
|---|---|---|
| ED/Primary care | 130M visits | CDC 2022 |
| Sexual clinics | 1.6M chlamydia cases | CDC 2022 |
| Global programs | 38.4M PLHIV | UNAIDS 2023 |
| Consumers | >$40B market | 2024 projection |
Cost Structure
COGS for kits & devices
Materials for membranes, reagents, plastics and packaging account for roughly 65% of unit COGS for kits and devices; membranes and reagents are the largest line items. Yield and scrap rates can swing gross margins by as much as 6–8 percentage points. Volume purchasing at million‑unit scale can cut component costs 15–25%. Freight volatility remained material in 2024, with ocean freight showing ±20% swings that affect landed cost.
Manufacturing & overhead
Manufacturing & overhead at OraSure (NASDAQ: OSUR) covers facility lease and utilities, equipment depreciation tied to diagnostic production lines, and CAPEX-backed validation/calibration systems; in fiscal 2024 these costs were a significant component of cost of goods sold relative to reported 2024 revenue of $153.4 million.
R&D and clinical studies
In 2024 OraSure concentrates R&D on assay development, prototypes, and rigorous verification/validation to support diagnostic robustness. Clinical trials are conducted to underpin regulatory submissions and label claims, often coordinated with KOL collaborations and peer-reviewed publications. Pipeline and line-extension spending funds follow-on indications and manufacturing scale-up tied to market access strategies.
Regulatory, quality & compliance
Regulatory, quality & compliance for OraSure demands recurring submission fees (FDA 510(k) ~$19,870 FY2024), regular audits and QMS maintenance budgets, plus continuous post-market surveillance and complaint handling workflows tied to CAPA reporting.
Labeling updates/localization and training/documentation systems add variable costs often concentrated in translation, regulatory review and LMS upkeep.
- 510(k) fee: ~$19,870 (FY2024)
- QMS audits/CAPA: ongoing budget line
- Post-market surveillance: complaint handling systems
- Labeling localization & training systems costs
Sales, marketing & distribution
OraSure’s sales, marketing and distribution costs center on a direct field force plus channel incentives and trade promotions; industry benchmarks (2024) put trade promotion spend at 5–10% of revenue. Retail slotting and e-commerce marketing add upfront placement costs; logistics, warehousing and cold-chain typically represent 3–5% of revenue. Customer support and education are ongoing G&A drivers tied to product adoption and regulatory training.
- Field force & channel incentives
- Trade promotions 5–10% (2024 benchmark)
- Retail slotting & e-commerce marketing
- Logistics/warehousing/cold-chain 3–5%
- Customer support & education
Materials dominate COGS (~65%); yield, volume buys and freight swings can change margins
Materials (membranes/reagents/plastics) drive ~65% of unit COGS; yield/scrap can swing gross margin 6–8 ppt and volume buys cut component costs 15–25%. Manufacturing/overhead and CAPEX-backed validation were material against 2024 revenue $153.4M. Regulatory, quality and trade promotion (5–10%) add recurring costs; ocean freight volatility ±20% affected landed cost in 2024.
| Line | 2024 metric |
|---|---|
| Revenue | $153.4M |
| Materials share | ~65% COGS |
| Yield impact | 6–8 ppt margin swing |
| Volume savings | 15–25% |
| 510(k) fee | $19,870 |
| Trade promo | 5–10% rev |
| Freight volatility | ±20% |
Revenue Streams
Point-of-care test sales
Revenue from HIV and infectious-disease rapid tests to clinics drives a core OraSure stream, supplying both CLIA-waived and professional-use devices to hospitals, community health centers and public-health programs. Recurring demand is supported by routine screening initiatives and STI/HIV public-health funding; the global rapid POC test market was estimated at about USD 3.6 billion in 2024. Pricing uses volume and contract tiers, with discounts for program and distributor agreements.
OTC diagnostic products
Sales of over-the-counter self-tests via retail and online form a core revenue stream, tapping a global self-test market valued at about $8.5 billion in 2023 with ~6.7% CAGR. Seasonal and campaign-driven lifts (holiday and flu seasons) create recurring spikes in unit sales and margin. Potential bundling and multipacks increase average order value, while international variants broaden addressable markets and distribution channels.
Molecular collection kits
Revenue from molecular collection kits (DNA/RNA and microbiome stabilization) supports OraSure Technologies (NASDAQ: OSUR) via OEM and direct channels, with a consumable, repeat-purchase model and custom configurations for partner labs and research customers in 2024.
Public sector contracts
Framework agreements and tenders with governments and NGOs secure large, multi-year purchase commitments for OraSure’s diagnostics and specimen-collection products, improving revenue visibility; contracts often include performance-based milestones and pricing tiers. Emergency orders during infectious-disease outbreaks can spike volumes and accelerate cash flow and backlog fulfillment.
- Framework agreements: multi-year commitments
- Performance-based milestones: payment tied to delivery/quality
- Emergency orders: rapid volume surges during outbreaks
Service & licensing
Service and licensing revenues include technical services, training, and validation support for clinical and OEM customers, with OEM/white-label IP royalties and select co-development/data fees supplementing product sales; in 2024 OraSure reported licensing and services contributing materially to recurring revenue streams.
- Technical services, training, validation
- OEM/white-label royalties
- Co-development and data fees
- Extended warranties and accessories
Revenue mix driven by HIV rapid POC, OTC self-tests and recurring molecular kit sales
OraSure’s revenue mix is led by HIV/infectious-disease rapid tests (global rapid POC test market ~USD 3.6B in 2024) and OTC self-tests (global self-test market ~USD 8.5B in 2023, ~6.7% CAGR). Molecular collection kits supply repeatable OEM and direct consumable sales, while multi-year government/NGO contracts and licensing/services add revenue visibility and recurring margin.
| Stream | 2024 market/value | Model | Notes |
|---|---|---|---|
| Rapid POC | USD 3.6B | Volume/contract | CLIA/professional |
| OTC self-test | USD 8.5B (2023) | Retail/online | Seasonal peaks |
| Molecular kits | — | Consumables/OEM | Repeat purchases |